Home
overview

SMi is delighted to announce the 4th annual Peptides conference returning to London in 2017!


In the past few years, new technological advancements in the pharma industry have influenced the growth of the global peptide therapeutics market, which is now estimated to reach US $23.70 billion by 2020, with an increased number of peptides now in the pipeline of many biotech companies.


Peptide manufacturers and suppliers have been developing and implementing new technologies to improve the peptide production, reduce manufacturing costs, and allow for more accurate formulations to enhance overall drug delivery. In addition, as cancer has been the most prominent sector in peptide therapeutics and is further expected to stay at the top, the market has been largely driven by the increased demand for peptides in cancer treatment. The increase in collaborations between biotech companies has also contributed to the market growing at this rate.


SMi’s 4th annual Peptides conference will give you the perfect platform to network, collaborate and learn over 2 days, featuring various key presentations by senior level industry professionals. With topics such as peptide formulation and delivery, as well as new advances in alternative peptide analysis technologies, Cell Penetrating Peptides, enhancements in synthesis mechanisms, analytical monitoring techniques, and many more.


You will have the opportunity to gather valuable new insight on assessing biophysical characterization, extending half-life, new formulations and routes of administration, and other pressing matters in the peptides industry.

 

http://bit.ly/2kG3Ei2

  • Gain new insight into the latest developments and innovations in peptide therapeutics, drug delivery systems, research and technology
  • Hear about beneficial ways to enhance and further develop your peptide design and manufacturing, allowing you to reduce costs and cut production time
  • Learn how to best assess new formulations and routes for administration of peptides
  • Meet and collaborate with some of the top players in the peptides industry, helping you make new connections for greater innovation in peptides research, therapeutics and technology

Previous attendees included:

 

Abzena; Albumedix; Almac Group; AmbioPharm; Bachem; Bachem Americas; Bachem Americas, Inc.; Bicycle Therapeutics; Bicycle Therapeutics Limited; BUCHI UK Ltd ; Chemi Spa; Complix NV; Cupid Peptide Company; Cupid Peptides ; Cyclogenix Ltd; DAISO Fine Chem GmbH; Haemostatix Ltd; Ipsen; Ipsen Research Laboratories; IRBM Science Park; Kition Research Limited; Ludwig Institute for Cancer Research; Marble Pharma Consult, sprl; MedImmune; Ministry Of Foreign Affairs; MorphoSys AG; MRC Technology; Pepticom LTD; Protagonist Therapeutics; Proxima Concepts Ltd; Sanofi-Aventis; Sanofi-Aventis Germany GmbH; Swedish Biomimetics 3000® Ltd; UCL School of Pharmacy; UCL/Astrazeneca; University Of Bristol; Zealand Pharma; Zealand Pharma A/S;

FEATURED SPEAKERS

Alastair Lawson

Alastair Lawson

Research Fellow, Vice President Structural Biology, UCB
Cecile Brocard

Cecile Brocard

Director Downstream Development, Boehringer Ingelheim
Craig Harris

Craig Harris

Head of Research Synthesis, Nestlé Skin Health
Elisabetta Bianchi

Elisabetta Bianchi

Head of Peptide Chemistry , IRBM Science Park

Alastair Lawson

Research Fellow, Vice President Structural Biology, UCB
Alastair Lawson

Alastair has been closely involved with the discovery of UCB/Celltech’s therapeutic antibodies, including Mylotarg, Cimzia, romosozumab, inotuzumab ozogamicin, dapirolizumab pegol, olokizumab, bimekizumab and UCB7665. Alastair led the development of UCB’s proprietary antibody variable region discovery platform, and is now applying structure-based, rational design to antibody discovery. He pioneered UCB’s small molecule protein/protein interaction initiative, in which information derived from antibodies is applied to the discovery and design of new chemical entities. Current research interests include the use of function-modifying antibody fragments to define specific conformations of target proteins, linking X-ray crystallography, molecular dynamics simulations and antibody technology to small molecule fragment screening.

Cecile Brocard

Director Downstream Development, Boehringer Ingelheim
Cecile Brocard

Cécile Brocard studied Biochemistry and Molecular Cell Biology in France, holds a PhD in Biochemistry from the University of Vienna (Austria) and has over 20-year experience in protein biochemistry.

Currently she is leading Downstream Development in Process Science at Boehringer Ingelheim Regional Center Vienna. As Head of Downstream Development she is responsible for DSP processes development for non-platform recombinant proteins expressed in microbial including, clinical supplies phase I/II/III and tech transfer to production. She heads a group composed of two downstream development units and a non-GMP pilot plant. Besides, she is critically involved in driving technology programs and strategic initiatives to develop innovation and improve process flows.

Craig Harris

Head of Research Synthesis, Nestlé Skin Health
Craig Harris

Dr. Craig Harris obtained his B.Sc. and Ph.D. at the University of Manchester (UMIST) in 1997. After a brief stay in PR&D at AZ, from 1999 he moved to Discovery Research working in the Oncology iMed for AZ working principally on kinase inhibition initially at the Alderley Park site then at the Reims site, France. After the closure of the Reims site in 2012, he was taken on as Head of Research Synthesis at for then Galderma (now, Nestlé Skin Health) Research Chemistry. In 2014, he was nominated as Senior Expert Scientist for Chemical Sciences.
During his career, he has won several prizes for publications and innovation in synthesis. Craig’s main interests lie in the word ‘Lean’ applied to chemical research: Rapid & selective synthesis of novel molecules for pharmacological targets. In addition to his background in the synthesis of novel kinase inhibitors as anti-cancer agents, Craig has developed a particular experience in the synthesis of peptidomimetics for targets in drug discovery.

Dieter Kadereit

Lab Head, Peptides & Insulins, IDD, R&D, Sanofi
Dieter Kadereit

Dieter Kadereit studied chemistry at the University of Hannover in Germany. After spending a year in Stanford, California with Prof. Wender he moved to the RWTH Aachen for his diploma research with Prof. Bolm and finally to the University of Karlsruhe for his PhD with Prof. Waldmann.
In the year 2000 Dieter joined Aventis as a laboratory head in chemistry. Soon he also became project team leader for his project and remained in that double role through several reorganizations and in different departments. Today he is working as laboratory head and project team leader in the Peptides & Insulins group in Sanofi’s Integrated Drug Discovery Research Platform.

Elisabetta Bianchi

Head of Peptide Chemistry , IRBM Science Park
Elisabetta Bianchi

Elisabetta Bianchi has been the Head of Peptide Chemistry at IRBM Science Park Pomezia (Italy) since 2010. In 2014 she obtained the Italian National Academic Qualifications as associate professor in Organic Chemistry and Molecular Biology. She started her career in the pharmaceutical industry in the Peptide Chemistry Group at Eniricerche followed by positions in Sclavo and Menarini Ricerche before joining IRBM in 1991. After full IRBM acquisition by Merck Research Laboratories in 2007 she was appointed Senior Investigator in the Peptide Center of Excellence at Merck. As project leader and member of Merck Early Development Teams she contributed to the preclinical and clinical development of peptide vaccines and peptide therapeutics. She is the author of 67 scientific publications in peer-reviewed journals and inventor in more than 30 patent applications.

Frank Thielmann

PMO & Operational Excellence Lead, Novartis
Frank Thielmann

Dr Thielmann graduated from University of Duesseldorf, Germany in 1996 with a diploma in Chemistry. This was followed by a PhD in Physical Chemistry in 1998 in the area of materials characterisation. Frank then worked for a private materials testing institute in Hannover, Germany before joining Surface Measurement Systems UK (SMS) in 2000. He stayed with SMS for eight years in different roles including global Head of Application Science. In this role, he was heavily involved in the development of novel characterisation methods for the challenges in the modern (bio)pharmaceutical industry with focus on solid dosage forms. Frank joined Novartis Pharma (Basel, Switzerland) in July 2007 as Formulation Lab Head. From August 2009 until February 2011 he managed the inhalation & device development group at the Horsham site, UK. Upon his return to Basel he took on the responsibility for the local inhalation technology platform until February 2012. Subsequently he joined Novartis Technical Operations where he was leading the setup of a new inhalation manufacturing facility and the transfer of the corresponding portfolio.
In December 2016 Frank joint the Biologics Technical Development & Manufacturing department as the Lead for PMO & Operational Excellence.
Dr Thielmann is member of the Steering Committee of the Material Science Focus Group in the British Academy of Pharmaceutical Sciences. He is an author and co-author of more than 25 articles in peer reviewed journals as well as author and co-author of more than 50 oral presentations at international conferences and seminars and over 100 scientific posters.

John Reilly

Senior Research Investigator, Novartis Institutes for BioMedical Research
John Reilly

Dr. Reilly is a Senior Research Investigator in the Department of Global Discovery Chemistry at Novartis Institute of Biomedical Sciences in Cambridge MA, USA. He currently leads the Chemistry Separations support team where there is a focus on providing purification and analytical characterization methodologies to support an expanding Chemistry unit. He completed both MSc. Birkbeck College in 1992 and Ph.D within Analytical Science Imperial College in 2002 after his initial BSc in Chemistry at Reading University in 1989. His research goals include the promotion of chromatographic characterization and purification methods and physicochemical affinity screens to investigate drug-like properties of molecules. Dr. Reilly has published >30 articles in many analytical journals such as J. Chromatography A, J. Med. Chem, J. Pharm. Biomed. Analysis, Chirality and Molecular Pharmacology. Dr. Reilly has been board member of the Chromatography Society in the UK and ChromSoc conference organiser and on the editorial board of “Chromatography Today” and “American Journal of Modern Chromatography.”

Jörgen Kjellgren Sjögren

Senior Research Scientist, Ferring Pharmaceuticals A/S
Jörgen Kjellgren Sjögren

Masters degree in Analytical Chemistry from Lund University, Sweden, in 1997 and PhD in Organic Chemistry from the Swedish University of Agricultural Sciences in Uppsala 2005. Worked with structure elucidation of peptides for >15 years utilising HPLC/UHPLC, MS and NMR and have >10 years experience of the pharmaceutical industry, 2½ years at Astra Zeneca, Lund, Sweden, and >11 years at Ferring Pharmaceuticals in Copenhagen, Denmark.

Lutz Jermutus

Senior Director, Technology, MedImmune
Lutz Jermutus

Chair for Day 2

.

Marion King

Analytical Development Manager, Ipsen
Marion King

Dr. Marion King is the Analytical Development Manager with Ipsen Manufacturing Ireland Ltd. She has over 13 years’ experience in the Pharmaceutical industry with 11 years working in the area of Analytical Development of peptides at Ipsen. Marion has a BSc in Analytical Chemistry from Cork Institute of Technology and a PhD from Dublin City University. Marion recently completed an MSc in Management and also leads a companywide Analytical Centre of Excellence (ACE) team. Marion is a member of the USP Biologics 1 – Peptides and Insulins Expert Committee and the JS3 Joint Subcommittee on biological reference standards.

Martin Will

Section Head MedChem, Sanofi
Martin Will

Martin Will received his MSc and PhD in Chemistry (1989) from Johann Wolfgang Goethe University in Frankfurt in Group of Horst Kessler working on conformational analysis of cyclic peptides using NMR and molecular dynamics. He started his industrial career 1989 at BASF where he held various positions in chemo-informatics and analytical chemistry. In 2001 he moved to Aventis (now Sanofi) taking over a position as section head analytical chemistry. His research was focused on new methods for automated structure validation and optimization of drug like properties. Currently, his group has a strong focus on peptide analytics and physico-chemistry.

Roger New

Co-founder & CSO, Proxima Concepts Ltd
Roger New

Roger New studied chemistry at Oxford and obtained a PhD in immunology at St Mary’s Hospital, London, before going to work in Liverpool for 14 years, first at the Department of Biochemistry, then at the School of Tropical Medicine and Hygiene. His research activities have centred on the creation of new technologies to improve the therapy of disease, during which time he has devised patented approaches to oral peptide delivery, vaccine carrier systems, and a technology for discovery of new therapeutics. He has acted as expert advisor in numerous institutions at home and overseas, has written a textbook on liposomes, and is honorary lecturer in Pharmaceutics at Kings College London. Dr New’s laboratory was the first to demonstrate the in vivo efficacy of liposomal amphotericin in leishmaniasis, a product which has now been commercialised for over ten years. He went into industry twenty years ago, first in Biocompatibles Ltd, then Cortecs, and is currently Co-founder and Executive Director of the biotech R&D company Proxima Concepts Ltd, with laboratories based in London. Development of the peptide delivery technology invented by Dr New has resulted in a product for oral administration of insulin, now in Phase II clinical trials, and licensed to large pharma in an emerging market. The discovery technology has yielded structures which can act as targeting agents, inhibit enzyme activity or change the behaviour of cells, and one peptide has been developed which is currently undergoing preclinical studies as a treatment for rheumatoid arthritis.

Sponsors and Exhibitors

Workshops

Oral Delivery of Peptides and Proteins
Workshop

Oral Delivery of Peptides and Proteins

Holiday Inn Kensington Forum
5th July 2017
London, United Kingdom

VENUE

Holiday Inn Kensington Forum

97 Cromwell Road , London, United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Sponsors and Exhibitors


Bachem

Sponsors and Exhibitors
http://www.bachem.com/

Bachem provides comprehensive services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based APIs. The group has a global reach with more experience and know-how than any other company in the industry. Bachem. Pioneering Partner for Peptides

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.